Autistic Disorder Clinical Trial
— VPHOfficial title:
A Prospective, Non-Randomized, Open-Label Study on the Clinical Effects of Hyperbaric Oxygen Therapy in Thai Autistic Children
| Verified date | April 2008 |
| Source | Vachira Phuket Hospital |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Thailand: Ministry of Public Health |
| Study type | Interventional |
Autism is a developmental and behavioral pattern which includes the triad of impairments, 1.
social interaction 2. social communication 3. imagination. Inevitable difficulties in the
treatment, managing and handle with autistic children are the main problems. Their memories
are seemingly in picture or photo records, which are difference from normal population.
There are many concepts but no concise in causative factors, including useful treatments,
useless and prolong remaining in many studies.
HBOT (Hyperbaric Oxygen Therapy) is a quite modern treatment in Thailand for nitrogen
imbalance (decompression sickness syndrome or Caisson disease). How can we apply it to treat
the autism? A hypothesis shows evidence that neurons surrounding the permanently damaged
epicenter of injury can be reactivated with increased oxygen. Oxygen exists in the blood in
two forms, combined with hemoglobin and dissolved in plasma. More oxygen is transported by
hemoglobin, but oxygen is delivered to the tissues in dissolved form by the liquid portion
of blood. HBOT can increase in plasma oxygen to the tissues including the brain. A little
change in oxygen can make the better improvements in : cognitive ability, socialization,
sleep, calmness, decreased stimming and language. It can make increased in Glutathione
(GSH), and Glutathione (GSH) can decreased in oxidative stress with effected to remove metal
compounds (mercury) to improve the autism.
This clinical trial study divided into 3 group populations 1. general autism 2.
post-treatment chiropractic autism 3. medicated autism. This comparative study shows the
major clinical symptoms before and after the treatment with HBOT. This study results and
analysis are the most important for our further projects planning.
| Status | Completed |
| Enrollment | 7 |
| Est. completion date | April 2008 |
| Est. primary completion date | April 2008 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 5 Years to 9 Years |
| Eligibility |
Inclusion criteria: 1. Both sexes 2. All aged-group 3. All educated group 4. Diagnosis - Autistic disorder, Autistic spectrums 5. Major symptoms - delayed development, delayed speech Exclusion criteria: 1. Uncontrolled severe explosive behaviours 2. Uncontrolled organic or physical symptoms such as seizure, ear infection 3. Severe phobic or fearful symptoms 4. No parent or caretaker |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| Thailand | Vachira Phuket Hospital | Phuket |
| Lead Sponsor | Collaborator |
|---|---|
| Vachira Phuket Hospital |
Thailand,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Developmental and Skill training assessment, Rajanukul Hospital 5th edition | 10 sessions assessment | Yes | |
| Secondary | Developmental and Skill training assessment, Rajanukul Hospital 5th edition | 20 sessions assessment | Yes |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03222375 -
SQUEDâ„¢ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism
|
N/A | |
| Completed |
NCT02568631 -
Improving Social Cognition for Adults With ASD by the Serious Game JeStiMulE Versus Controls
|
N/A | |
| Completed |
NCT02708290 -
Mental Imagery Therapy for Autism (MITA) - an Early Intervention Computerized Language Training Program for Children With ASD
|
||
| Completed |
NCT02369445 -
Investigation of Teacher-Mediated Toilet Training Using a Manualized Moisture Alarm Intervention
|
N/A | |
| Completed |
NCT01617460 -
A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Autistic Disorder
|
Phase 3 | |
| Completed |
NCT01592747 -
Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine
|
Phase 2 | |
| Completed |
NCT01400269 -
An Evaluation of a Developmentally-Based Parent Training Program for Children With Autism
|
N/A | |
| Active, not recruiting |
NCT02442115 -
Impact of Improving GI Symptoms on Autism Symptoms and Oxidative Stress
|
||
| Completed |
NCT00926471 -
Social Skills and Anxiety Reduction Treatment for Children and Adolescents With Autism Spectrum Disorders
|
Phase 1 | |
| Completed |
NCT00692315 -
Treating Oxidative Stress in Children With Autism
|
N/A | |
| Completed |
NCT00365859 -
Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD)
|
Phase 3 | |
| Completed |
NCT00198107 -
Evaluating the Effectiveness of Aripiprazole and D-Cycloserine to Treat Symptoms Associated With Autism
|
Phase 3 | |
| Completed |
NCT00095420 -
Relationship Training for Children With Autism and Their Peers
|
N/A | |
| Completed |
NCT00027404 -
Study of Fluoxetine in Adults With Autistic Disorder
|
N/A | |
| Recruiting |
NCT05910502 -
Project AFECT (Autism Family Empowerment Coaching and Training Program)
|
N/A | |
| Completed |
NCT04820998 -
Living in a Precarious Situation With an Autistic Child: What Are the Issues at Stake for Support in Care
|
||
| Withdrawn |
NCT05413187 -
A Trial to Assess the Efficacy and Safety of Medical Grade Cannabis in Children Diagnosed With Autism Spectrum Disorder
|
Phase 2 | |
| Recruiting |
NCT02275455 -
Design Of WELL Being Monitoring Systems, Application in Autism
|
N/A | |
| Completed |
NCT02766101 -
Manville Moves: an Exercise Intervention for Behavioral Regulation Among Children With Behavioral Health Challenges
|
N/A | |
| Completed |
NCT01977248 -
Sensorimotor Affect Relationship-based Therapy (SMART) for Children With Autism Spectrum Disorders Ages 2-12
|
N/A |